Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Revenue | $440.9M | $305.5M | $243.9M | $271.9M | $299.5M | $219.6M | $189.9M |
| Cost of revenue | $257.9M | $168.0M | $126.9M | $138.9M | $165.0M | $120.3M | $89.9M |
| Gross profit | $183.0M | $137.4M | $117.0M | $132.9M | $134.5M | $99.4M | $100.0M |
| Gross margin | 41.5% | 45.0% | 48.0% | 48.9% | 44.9% | 45.2% | 52.7% |
| R&D | $140.5M | $181.3M | $159.9M | $189.4M | $222.6M | $205.4M | $101.6M |
| Operating income | −$188.8M | −$213.8M | −$185.2M | −$254.2M | −$324.0M | −$321.4M | −$240.6M |
| EBITDA | −$173.6M | −$191.5M | −$164.9M | −$228.0M | −$277.9M | −$291.9M | −$155.9M |
| Net income | −$183.5M | −$250.9M | −$183.4M | −$217.5M | −$311.7M | −$666.7M | −$280.9M |
| Net margin | -41.6% | -82.1% | -75.2% | -80.0% | -104.1% | -303.5% | -147.9% |
| EPS (diluted) | -9.03 | -14.24 | -9.02 | -9.96 | -13.80 | -28.01 | -10.88 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $251M | $-7.80 | $-7.80–$-7.80 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ME.
No tracked institution reports a position in ME as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-10-16 | 1-for-20reverse |
No one on the platform has traded ME yet.
| $3M |
| — |
| GENEGenetic Technologies Limited | $0.77 | +0.00% | $111M | — |
| GHGuardant Health, Inc. | $153.74 | +3.03% | $20.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 4.4× historical median P/S.
Fair value ≈ $36.67 · price $0.61 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.